Depressive disorder
|
0.600 |
Therapeutic
|
disease |
CTD_human |
Overall, the results appear to sustain the importance of the FSL rats as an animal model of depression in view of the impairment of NPY genes and the ability of fluoxetine treatment to normalize NPY-related gene expression selectively in this strain.
|
9729278 |
1998 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
CTD_human |
Overall, the results appear to sustain the importance of the FSL rats as an animal model of depression in view of the impairment of NPY genes and the ability of fluoxetine treatment to normalize NPY-related gene expression selectively in this strain.
|
9729278 |
1998 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
These findings point to the potential of the NPY system for developing novel pharmacological treatments of stress-related disorders, including anxiety and depression.
|
12013027 |
2002 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Our present findings are in line with an extensive animal literature, and further support the notion that impaired NPY function could contribute to depressive illness.
|
14757324 |
2004 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neurochemical and/or pharmacological evidence suggests that the FSL rat exhibits changes consistent with the cholinergic, serotonergic, dopaminergic, NPY, and circadian rhythm models but not the noradrenergic, HPA axis or GABAergic models of depression.
|
15925699 |
2005 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
For example, NPY is consistently involved in anxiety-related behaviors and there is increasing support for a role of this peptide in mood disorders such as depression.
|
16611091 |
2006 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Neuropeptide Y (NPY) was shown to modulate anxiety- and depression-related behaviors in various animal models.
|
16691011 |
2006 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors.
|
17572454 |
2007 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
CTD_human |
The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors.
|
17572454 |
2007 |
Depressive disorder
|
0.600 |
Therapeutic
|
disease |
CTD_human |
The data support our hypothesis that the NPY system dysregulation constitutes one of the biological underpinnings of depression and that one common mechanism of action of antidepressive treatment modalities may be effects on NPY and its receptors.
|
17572454 |
2007 |
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Pro7 allele of preproNPY protected against depression among Swedes.
|
19264362 |
2009 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
However, novel evidence from polymorphisms in the prepro-NPY gene has shed new light on the potential clinical relevance of NPY in depression.
|
19782662 |
2010 |
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Five NPY gene variants were investigated for an influence on antidepressant treatment response in a sample of 256 patients with depression.
|
19854625 |
2010 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
These data suggest that changes of plasma levels of anti-NPY autoAbs are relevant to altered mood, while changes of their affinity may participate in altered appetite and body weight in patients with depressive disorder.
|
22365482 |
2012 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data suggest that changes of plasma levels of anti-NPY autoAbs are relevant to altered mood, while changes of their affinity may participate in altered appetite and body weight in patients with depressive disorder.
|
22365482 |
2012 |
Depressive disorder
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Statistical analysis showed a significant correlation between the SNP sites rs16139 in NPY and the morbidity of depression.
|
23468908 |
2013 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Statistical analysis showed a significant correlation between the SNP sites rs16139 in NPY and the morbidity of depression.
|
23468908 |
2013 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
However, alterations in anxiety- and depression-regulating genes were present in the hypothalamus of BACHD mice including reduced mRNA expression of neuropeptide Y, tachykinin receptor 3 and vesicular monoamine transporter type 2 as well as increased expression of cocaine and amphetamine regulated transcript.
|
23697793 |
2013 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
However, alterations in anxiety- and depression-regulating genes were present in the hypothalamus of BACHD mice including reduced mRNA expression of neuropeptide Y, tachykinin receptor 3 and vesicular monoamine transporter type 2 as well as increased expression of cocaine and amphetamine regulated transcript.
|
23697793 |
2013 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
NPY has recently gained much attention as an endogenous antiepileptic and antidepressant agent, as drugs with antiepileptic and/or mood-stabilizing properties may exert their action by increasing NPY concentrations, which in turn can reduce anxiety and depression levels, dampen seizures or increase seizure threshold.
|
23994577 |
2013 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Using a recombinant adeno-associated viral (rAAV) vector, we addressed this idea by testing effects on anxiolytic- and depression-like behaviours in adult mice after overexpression of NPY transgene in the amygdala and/or hippocampus, two brain regions implicated in emotional behaviours.
|
25267070 |
2014 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
PSYGENET |
Among all candidate substrates, DPP4 displays highest affinity for NPY, an endogenous anxiolytic neurotransmitter that is suggested as a candidate biomarker in post-traumatic stress disorder (PTSD) and depression.
|
25635612 |
2015 |
Depressive disorder
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the behavioral indicators of depression showed strong correlations with the serum levels and the hippocampal content of NPY.
|
28582442 |
2017 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
Both NPY and CGRP were higher in PD patients with comorbid depression compared to MDD patients.
|
28659833 |
2017 |
Depressive disorder
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this review, we present an overview of findings with regard to the NPY system in relation to anxiety and stress, acute as well as chronic; furthermore we discuss post-traumatic stress disorder and, in part depression.
|
28824541 |
2017 |